A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Trial Profile

A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 05 Oct 2017 This trial was completed in Greece (end date: 2017-06-02), according to European Clinical Trials Database.
    • 26 Sep 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
    • 30 May 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top